



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 06/19/2017 08:16
Last Report Issued 04/10/2017 13:19

88888
Clinical Example Report
Attn: IT Department
200 Welsh Road
Horsham, PA 19044-2208

Patient Name 0570B-POS
Patient ID 0570B-POS
Chain 17000768
Age Not Given DOB Not Given
Gender Not Given
Workorder 17000768
Received 04/10/2017 12:42

Sample ID 17000768-001
Matrix Blood
Patient Name 0570B-POS
Patient ID 0570B-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

0570B Designer Benzodiazepines, Blood (Forensic)

Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Bromazepam 50 ng/mL 5.0

Bromazepam is a benzodiazepine drug that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries.

Average peak plasma concentrations following a single 3 mg, 6 mg and 12 mg dose were reported to be 10 ng/mL at 8 hours, 83 ng/mL at 2 hours and 130 ng/mL at 1-4 hours after dosing, respectively. Chronic oral administration of 9 mg daily resulted in an steady-state plasma concentrations of 81-150 ng/mL (Average = 120 ng/mL). Reported half-lives are 12 - 27 hours.

The blood to serum/plasma ratio is not known.

Results for sample 17000768-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 17000768-001
Matrix Blood
Patient Name 0570B-POS
Patient ID 0570B-POS

Collect Dt/Tm Not Given
Source Not Given

| Analysis and Comments | Result | Units | Reporting Limit | Notes |
|---|--------|-------|-----------------|-------|
| <p>Clonazepam</p> <p>Clonazepam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.</p> | 50 | ng/mL | 5.0 | |
| <p>Pyrazolam</p> <p>Pyrazolam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.</p> <p>The peak serum concentration following a single 1 mg oral dose was reported to be approximately 50 ng/mL at 3 hours. Pyrazolam may be detected in serum for at least 4 days after use. The reported half-life is 17 hours.</p> <p>The blood to serum/plasma ratio is not known.</p> <p>Substance(s) known to interfere with the identity and/or quantity of the reported result: Oxazepam.</p> | 50 | ng/mL | 5.0 | |
| <p>Meclonazepam</p> <p>Meclonazepam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.</p> <p>Substance(s) known to interfere with the identity and/or quantity of the reported result: Oxazepam.</p> | 50 | ng/mL | 5.0 | |
| <p>Flubromazolam</p> | 50 | ng/mL | 2.0 | |

Results for sample 17000768-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 17000768-001
Matrix Blood
Patient Name 0570B-POS
Patient ID 0570B-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Contains rows for Etizolam and Deschloroetizolam with detailed analysis comments and numerical results.

Results for sample 17000768-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 17000768-001
Matrix Blood
Patient Name 0570B-POS
Patient ID 0570B-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Contains detailed text for Delorazepam and Phenazepam, including their pharmacological properties and clinical data.

Results for sample 17000768-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 17000768-001
Matrix Blood
Patient Name 0570B-POS
Patient ID 0570B-POS

Collect Dt/Tm Not Given
Source Not Given

| Analysis and Comments | Result | Units | Reporting Limit | Notes |
|---|--------|-------|-----------------|-------|
| <p>Average peak plasma concentrations following a single 3 mg and 5 mg dose were reported to be 24 ng/mL and 38 ng/mL at 4 hours after dosing, respectively. The reported half-life is 60 hours.</p> <p>The blood to serum/plasma ratio is not known.</p> <p>Substance(s) known to interfere with the identity and/or quantity of the reported result: Nordiazepam.</p> | 50 | ng/mL | 5.0 | |
| <p>Diclazepam</p> <p>Diclazepam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.</p> <p>The peak serum concentration following a single 1 mg oral dose was reported to be approximately 3.4 ng/mL at 3 hours. Diclazepam is metabolized to the active compounds delorazepam (chlordesmethyldiazepam), lormetazepam and lorazepam. Diclazepam may be detected in serum for at least to 4 days after use. The reported half-life is 42 hours.</p> <p>The blood to serum/plasma ratio is not known.</p> | | | | |